Category: Biotechnology

Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Collaboration with Novartis

Gibson Dunn advises Arrowhead on Novartis deal for ARO-SNCA, with $200M upfront, up to $2B milestones, and royalties on sales.